Omics Sequencing Market
Report ID: SQMIG35J2807
Report ID: SQMIG35J2807
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2807 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
174
|Figures:
79
Global Omics Sequencing Market size was valued at USD 18.6 Billion in 2024 and is poised to grow from USD 21.33 Billion in 2025 to USD 63.92 Billion by 2033, growing at a CAGR of 14.7% during the forecast period (2026-2033).
The global omics sequencing market encompasses technologies that decode DNA, RNA, proteins and metabolites, enabling comprehensive biological insight for research, diagnostics and drug development. Its importance stems from the ability to translate molecular data into precision medicine, agricultural improvement and environmental monitoring. Historically, the market emerged from early Sanger sequencing in the 1970s, progressed to high‑throughput next‑generation platforms in the late 2000s, and now embraces single‑cell and long‑read solutions. This evolution accelerated as costs fell below $100 per human genome, prompting large‑scale initiatives such as the 1000 Genomes Project and national biobanks that demonstrate the market’s expanding relevance for scientific advancement.
Regulatory endorsement of personalized therapeutics now drives the second‑wave expansion of the omics sequencing market, because insurers and health agencies increasingly require molecular validation before approving targeted drugs. When a pharmaceutical company demonstrates that a biomarker predicts response, payers reimburse companion diagnostics, which in turn incentivizes laboratories to invest in high‑throughput sequencers and bioinformatic pipelines. This feedback loop fuels adoption in oncology, where FDA‑cleared assays such as Guardant360 enable non‑invasive tumor profiling and directly boost sequencing volume. Parallelly, agricultural firms leverage CRISPR‑guided genotype data to breed climate‑resilient crops, creating a parallel market for plant‑omics services that capitalizes on the same cost‑reduction significant trends.
How is AI-driven automation reshaping the global omics sequencing market?
AI driven automation is redefining the global omics sequencing market by linking data generation directly to intelligent analysis pipelines. Machine learning models now guide sample preparation, reduce hands on time and predict optimal run parameters which accelerates turnaround and improves reproducibility. Laboratories adopt integrated robots that handle library construction, quality control and loading freeing scientists to focus on interpretation. This shift expands access to high throughput sequencing for clinical research, drug discovery and population genomics while lowering operational costs and minimizing human error. As a result the market experiences faster scaling and broader geographic reach.
Illumina in March 2024, introduced an AI powered automation platform that streamlines library preparation and run scheduling, cutting cycle time and boosting data quality which fuels market growth and operational efficiency across research and clinical labs. The system integrates real time analytics and predictive maintenance, allowing continuous throughput without downtime and encouraging broader adoption of omics technologies worldwide.
Market snapshot - (2026-2033)
Global Market Size
USD 18.6 Billion
Largest Segment
Genomics
Fastest Growth
Epigenomics
Growth Rate
14.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global omics sequencing market is segmented by omics type, technology, application, end user, workflow, product type and region. Based on omics type, the market is segmented into Genomics, Transcriptomics, Epigenomics and Metagenomics. Based on technology, the market is segmented into Next-Generation Sequencing and Third-Generation Sequencing. Based on application, the market is segmented into Clinical Diagnostics, Drug Discovery, Agricultural Research and Others. Based on end user, the market is segmented into Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories and Others. Based on workflow, the market is segmented into Sample Preparation, Sequencing and Data Analysis. Based on product type, the market is segmented into Instruments, Consumables, Software and Services. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Genomics segment dominates because it provides the foundational DNA blueprint that drives virtually all downstream biological investigations. Its widespread adoption stems from mature protocols, extensive reference databases, and robust validation frameworks that reduce uncertainty for both research and clinical users. This entrenched position fuels continual investment, reinforcing its centrality in driving innovations across discovery, diagnostics, and therapeutic development across diverse species and complex disease models enabling precision health initiatives worldwide.
Meanwhile, Epigenomics segment emerges as the most rapidly expanding area because the growing appreciation of gene regulation mechanisms is driving demand for methylation and chromatin accessibility profiling. Novel assay kits and portable sequencers are lowering barriers, while clinical research into cancer and neurodegenerative disorders fuels adoption, positioning epigenomic analysis as a catalyst for future market depth.
Next Generation Sequencing segment leads because it offers high throughput, reliable accuracy, and well established library workflows that meet the scale required by most research and clinical projects. Continuous reductions in reagent cost and widespread instrument availability create a familiar ecosystem that encourages broad adoption. These strengths make it the default choice for generating massive data volumes, sustaining the core revenue engine of the omics sequencing market.
Conversely, Third Generation Sequencing segment is witnessing the strongest growth momentum because its ability to produce ultra long reads resolves complex genomic regions and structural variation without extensive assembly. Emerging single molecule chemistry and portable devices are attracting precision medicine initiatives and de novo assembly projects, expanding market horizons and creating new revenue streams.
To get detailed segments analysis, Request a Free Sample Report
North America maintains a leading edge through a confluence of world‑class research institutions, extensive venture investment, and a regulatory environment that encourages innovation. The region benefits from deep integration of academia, biotech firms, and health‑care providers, fostering rapid translation of omics discoveries into clinical practice. Strong emphasis on personalized medicine drives demand for sophisticated sequencing platforms, while mature data‑analytics ecosystems support large‑scale genomic data handling. Collaborative networks spanning government agencies and private enterprises further accelerate technology adoption, ensuring that North America remains the benchmark for scientific rigor and commercial viability in the omics sequencing arena.
Omics Sequencing Market in the United States thrives on a dense cluster of biotech hubs, pioneering research universities, and a culture of entrepreneurial risk‑taking. Robust federal and private funding streams enable continuous advancement of sequencing technologies, while health‑care systems actively integrate genomic insights into patient care pathways. Strategic partnerships between technology providers and clinical labs accelerate product deployment, and a proactive regulatory framework streamlines market entry for innovative assays, reinforcing the United States as a catalyst for global omics progress.
Omics Sequencing Market in Canada leverages strong governmental support for life‑science research and a collaborative academic landscape. Emphasis on public‑private partnerships nurtures innovation ecosystems that bridge discovery and application. Health‑care networks increasingly incorporate genomic testing, driving demand for advanced sequencing solutions. A focus on data stewardship and ethical frameworks positions Canada as a trusted environment for handling sensitive omics information, further stimulating investment and adoption across research and clinical domains.
Europe’s expansion reflects a unified commitment to precision health, bolstered by coordinated research initiatives and cross‑border funding mechanisms. The region’s regulatory harmonization facilitates smoother market entry for new sequencing platforms, while a strong tradition of academic excellence fuels continuous methodological breakthroughs. Collaborative consortia link leading universities with biotech firms, encouraging technology transfer and joint ventures. Growing clinical adoption of genomics in personalized treatment regimens, combined with a mature infrastructure for data sharing, propels Europe’s omics sequencing market toward a trajectory of sustained growth and innovation.
Omics Sequencing Market in Germany is anchored by a dense network of research institutes and a robust pharmaceutical sector that prioritize genomic research. Government incentives encourage high‑throughput sequencing projects, while industry alliances accelerate translation of discoveries into therapeutic pipelines. Advanced bioinformatics capabilities and a strong focus on standardization support reliable data generation, reinforcing Germany’s position as a dominant hub for omics technology development and implementation across both academic and commercial settings.
Omics Sequencing Market in the United Kingdom experiences rapid growth through strategic investment in genomic research infrastructure and a vibrant biotech ecosystem. National initiatives promote large‑scale sequencing programs, fostering collaborations between universities, hospitals, and start‑up innovators. The integration of genomics into the National Health Service accelerates clinical uptake, while a supportive policy environment encourages venture capital flow into emerging sequencing companies, establishing the United Kingdom as one of the fastest‑growing markets in the European omics landscape.
Omics Sequencing Market in France is emerging as a dynamic arena propelled by strong public research funding and a growing number of biotech enterprises. Collaborative frameworks link academic laboratories with industry partners, facilitating technology transfer and the development of novel sequencing applications. Health‑care providers increasingly adopt genomic testing for diagnostic and therapeutic purposes, and a focus on ethical data management bolsters confidence in omics initiatives, positioning France as an emerging contributor to Europe’s overall market momentum.
Asia Pacific advances its role through aggressive adoption of next‑generation sequencing technologies and strategic government programmes that prioritize genomic research. The region’s large and diverse patient populations provide unparalleled opportunities for large‑scale studies, driving demand for high‑capacity sequencing solutions. Strong manufacturing capabilities enable cost‑effective production of instruments and reagents, while partnerships between multinational firms and local research institutions accelerate technology diffusion. An emphasis on building bioinformatics talent and data‑sharing consortia further consolidates Asia Pacific’s emergence as a pivotal contributor to global omics sequencing progress.
Omics Sequencing Market in Japan benefits from a longstanding commitment to scientific excellence and a sophisticated health‑care infrastructure. National research agencies allocate substantial resources toward genomics, fostering collaborations between universities, hospitals, and biotech firms. The integration of sequencing data into clinical decision‑making processes is increasingly commonplace, and a focus on precision medicine drives demand for advanced platforms. Strong intellectual property protections and a culture of meticulous quality assurance reinforce Japan’s leadership in high‑resolution omics applications.
Omics Sequencing Market in South Korea is propelled by a vibrant biotech sector and aggressive public investment in genomics research. Collaborative ecosystems connect leading universities with innovative start‑ups, expediting the development of cutting‑edge sequencing technologies. Health‑care providers are rapidly incorporating genomic insights into therapeutic strategies, while an emphasis on data analytics cultivates a skilled workforce capable of managing complex omics datasets. The combination of manufacturing expertise and supportive policy frameworks positions South Korea as a key driver of regional market expansion.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rapid Adoption of Next‑Generation Sequencers
Expanding Applications in Precision Medicine
High Capital Investment Requirements
Complex Data Interpretation Challenges
Request Free Customization of this report to help us to meet your business objectives.
The omics sequencing market is shaped by intense competition among incumbents such as Illumina, Thermo Fisher Scientific and Oxford Nanopore, driving rapid innovation and consolidation. Recent M&A activity includes Illumina’s acquisition of GRAIL, while Thermo Fisher’s partnership with BGI expands sample throughput. Oxford Nanopore’s launch of the PromethION X2 platform exemplifies technology‑focused differentiation, accelerating adoption across clinical and research applications.
Top Player’s Company Profile
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global omics sequencing market is being propelled primarily by the rapid adoption of next‑generation sequencers which lower per‑sample costs and accelerate discovery across research and clinical labs, while expanding applications in precision medicine further amplify demand by linking molecular data directly to patient treatment decisions. The genomics segment remains the clear leader because DNA sequencing provides the foundational blueprint for all downstream analyses. North America dominates the market due to its strong research ecosystem, venture capital and supportive regulatory framework. However, the high capital investment required to acquire advanced instruments and set up dedicated facilities acts as a significant restraint on broader adoption.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 18.6 Billion |
| Market size value in 2033 | USD 63.92 Billion |
| Growth Rate | 14.7% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Omics Sequencing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Omics Sequencing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Omics Sequencing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Omics Sequencing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Omics Sequencing Market size was valued at USD 18.6 Billion in 2024 and is poised to grow from USD 21.33 Billion in 2025 to USD 63.92 Billion by 2033, growing at a CAGR of 14.7% during the forecast period (2026-2033).
The omics sequencing market is shaped by intense competition among incumbents such as Illumina, Thermo Fisher Scientific and Oxford Nanopore, driving rapid innovation and consolidation. Recent M&A activity includes Illumina’s acquisition of GRAIL, while Thermo Fisher’s partnership with BGI expands sample throughput. Oxford Nanopore’s launch of the PromethION X2 platform exemplifies technology‑focused differentiation, accelerating adoption across clinical and research applications. 'Illumina, Inc.', 'PacBio', 'Oxford Nanopore Technologies plc', 'Thermo Fisher Scientific Inc.', 'BGI Genomics Co., Ltd.', 'QIAGEN N.V.', 'Roche Holding AG', 'Agilent Technologies, Inc.', 'Element Biosciences', 'Singular Genomics Systems, Inc.', 'Complete Genomics', 'Standard BioTools Inc.', 'Azenta, Inc.', 'Integrated DNA Technologies, Inc.', 'Eurofins Scientific SE', 'Novogene Co., Ltd.', 'Genewiz', 'Macrogen, Inc.', 'SeqMatic LLC', 'GeneDx Holdings Corp.'
Rapid adoption of advanced sequencing instruments enables laboratories to generate larger data sets with greater speed and accuracy, which in turn accelerates discovery cycles across genomics, transcriptomics, and epigenomics. This capability lowers per‑sample costs through economies of scale, encourages broader participation from academic and clinical researchers, and fuels demand for complementary consumables and bioinformatics services, collectively driving robust expansion of the global omics sequencing market as institutions seek to integrate multi‑omics insights into therapeutic development and personalized healthcare strategies, creating sustained revenue streams for vendors.
Personalized Medicine Acceleration: Healthcare providers worldwide are increasingly adopting omics sequencing to tailor therapies to individual genetic profiles, driving demand for rapid, high‑throughput platforms. This shift is propelled by clinician awareness of actionable biomarkers, patient expectations for precision interventions, and reimbursement models that reward outcome‑based care. As pharmaceutical companies integrate sequencing data early in drug development, the ecosystem supports tighter feedback loops, shortening timelines from target identification to clinical trial enrollment and creating sustained growth for sequencing service providers across emerging global markets.
Why does North America Dominate the Global Omics Sequencing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
